Choong Ang Vaccine Laboratory
KOSDAQ:072020
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Choong Ang Vaccine Laboratory
Income from Continuing Operations
Choong Ang Vaccine Laboratory
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Choong Ang Vaccine Laboratory
KOSDAQ:072020
|
Income from Continuing Operations
₩6.7B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
14%
|
|
|
Yuhan Corp
KRX:000100
|
Income from Continuing Operations
₩185.3B
|
CAGR 3-Years
27%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
4%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Income from Continuing Operations
₩253.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Income from Continuing Operations
₩187.1B
|
CAGR 3-Years
23%
|
CAGR 5-Years
61%
|
CAGR 10-Years
1%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Income from Continuing Operations
₩12B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-4%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Income from Continuing Operations
₩20.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
Choong Ang Vaccine Laboratory
Glance View
Choong Ang Vaccine Laboratory Co., Ltd. engages in the manufacture and sale of animal medicines and products. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2003-10-31. The firm provides veterinary vaccines for fowl, dogs, pigs, cattle, rabbits, cats, fishes and others under the brand name SuiShot, PoulShot, Canishot, BoviShot, FeliShot, RabbiShot and AquaShot. The firm also provides diagnosis services, and distributes other veterinary drugs, such as antibiotics, anthelmintics, disinfectants and feed additives. The firm distributes its products within domestic market and to overseas markets.
See Also
What is Choong Ang Vaccine Laboratory's Income from Continuing Operations?
Income from Continuing Operations
6.7B
KRW
Based on the financial report for Sep 30, 2025, Choong Ang Vaccine Laboratory's Income from Continuing Operations amounts to 6.7B KRW.
What is Choong Ang Vaccine Laboratory's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
14%
Over the last year, the Income from Continuing Operations growth was -2%. The average annual Income from Continuing Operations growth rates for Choong Ang Vaccine Laboratory have been -6% over the past three years , 6% over the past five years , and 14% over the past ten years .
